Loading...
•
Mar 31, 2023
Amneal Q1 2023 Earnings Report
Amneal's Q1 2023 earnings were announced, revealing a net revenue increase and affirming the full year guidance.
Key Takeaways
Amneal Pharmaceuticals reported a strong start to 2023 with a 12% increase in net revenue to $558 million compared to the first quarter of 2022. The company's performance was driven by growth across all three business segments. While the company reported a net loss of $7 million, adjusted EBITDA increased by 16% to $116 million. The company is affirming its full year 2023 guidance.
Net revenue for Q1 2023 reached $558 million, a 12% increase year-over-year.
GAAP net loss was $7 million, with a diluted loss per share of $0.05.
Adjusted EBITDA stood at $116 million, a 16% increase year-over-year.
Adjusted diluted EPS was $0.12, consistent with the first quarter of 2022.
Revenue by Segment
Forward Guidance
Amneal is affirming its previously provided full year 2023 guidance.
Positive Outlook
- Net revenue between $2.25 billion and $2.35 billion
- Adjusted EBITDA between $500 million and $530 million
- Adjusted diluted EPS between $0.40 and $0.50
- Operating cash flow between $200 million and $230 million
- Capital expenditures between $50 million and $60 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...